Interim report January-March 2012

Reporting period January – March

  · Orders received rose by 10.6% to SEK
5,795 M (5,241), and grew organically by 1.2%
  · Net sales increased by 12.3%
to SEK 5,246 M (4,671), and grew organically by 2.2%
  · Profit before tax rose
by 0.4% to SEK 570 M (568)
  · Net profit increased by 0.5% to SEK 422 M
(420)
  · Earnings per share increased by 0.6% to SEK 1.76 (1.75)
  · EBITA
before restructuring rose by 6.6% to SEK 854 M (801)
  · Strong cash flow
  ·
Favourable earnings outlook for 2012

First quarter 2012

Orders
received

The Group’s orders received grew organically by 1.2%. Despite a weak
trend in orders received during the quarter, demand is deemed to be in line with
plans and the Group continues to expect the rate of organic volume growth for
the full-year to exceed the preceding year.

For Medical Systems, organic
orders received rose by nearly 1%. In the year-earlier period, normalised orders
received increased organically by 7% (adjusted for a major order from Brazil).
Extended Care’s orders received declined organically by 0.2%, primarily due to a
weaker volume trend in North America, which experienced highly favourable orders
received in the corresponding period in the preceding year. Infection Control’s
orders received rose organically by 3.6%, with strong growth in both North
America and in the emerging markets.

The volume trend for the newly acquired
Atrium, which is not included in the calculation of organic orders received, was
very strong.Teleconference with CEO Johan Malmquist and CFO Ulf Grunander:
19th
of April 2012 at 15:00 CET.
Sweden: + 46 (0)8 506 857 59
UK dial in number:
+44 (0)207 108 6303
GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions and intensive
care.
The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.